Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.

Naito T, Udagawa H, Umemura S, Sakai T, Zenke Y, Kirita K, Matsumoto S, Yoh K, Niho S, Tsuboi M, Ishii G, Goto K.

Lung Cancer. 2019 Oct 13;138:35-42. doi: 10.1016/j.lungcan.2019.10.009. [Epub ahead of print]

PMID:
31630044
2.

Proportion of goblet cell is associated with malignant potential in invasive mucinous adenocarcinoma of the lung.

Oki T, Aokage K, Ueda T, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Funai K, Tsuboi M, Ishii G.

Pathol Int. 2019 Sep;69(9):526-535. doi: 10.1111/pin.12853.

PMID:
31559671
3.

Development of Immortalized Human Tumor Endothelial Cells from Renal Cancer.

Maishi N, Kikuchi H, Sato M, Nagao-Kitamoto H, Annan DA, Baba S, Hojo T, Yanagiya M, Ohba Y, Ishii G, Masutomi K, Shinohara N, Hida Y, Hida K.

Int J Mol Sci. 2019 Sep 17;20(18). pii: E4595. doi: 10.3390/ijms20184595.

4.

Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.

Ota T, Kirita K, Matsuzawa R, Udagawa H, Matsumoto S, Yoh K, Niho S, Ishii G, Goto K.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2495-2506. doi: 10.1007/s00432-019-03012-z. Epub 2019 Sep 7.

PMID:
31494736
5.

Impressive response to nivolumab of non-small-cell lung cancer containing sarcomatoid components.

Ota T, Niho S, Kirita K, Ishii G, Tsuboi M, Goto K.

Respirol Case Rep. 2019 Aug 20;7(8):e00477. doi: 10.1002/rcr2.477. eCollection 2019 Nov.

6.

Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma.

Ichikawa T, Aokage K, Miyoshi T, Tane K, Suzuki K, Makinoshima H, Tsuboi M, Ishii G.

Lung Cancer. 2019 Oct;136:57-64. doi: 10.1016/j.lungcan.2019.08.003. Epub 2019 Aug 9.

PMID:
31445355
7.

Interaction between cancer cells and cancer-associated fibroblasts after cisplatin treatment promotes cancer cell regrowth.

Hisamitsu S, Miyashita T, Hashimoto H, Neri S, Sugano M, Nakamura H, Yamazaki S, Ochiai A, Goto K, Tsuboi M, Ishii G.

Hum Cell. 2019 Oct;32(4):453-464. doi: 10.1007/s13577-019-00275-z. Epub 2019 Aug 22.

PMID:
31441010
8.

Large pulmonary sclerosing pneumocytoma with massive necrosis and vascular invasion: a case report.

Sakai T, Miyoshi T, Umemura S, Suzuki J, Nakasone S, Okada S, Tane K, Aokage K, Goto K, Motoi N, Ishii G, Tsuboi M.

Oxf Med Case Reports. 2019 Jul 1;2019(7). pii: omz066. doi: 10.1093/omcr/omz066.

9.

Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancer-associated fibroblasts with EGFR-TKI resistance-promoting phenotype: A study of 18 cases of cancer-associated fibroblasts.

Suzuki E, Yamazaki S, Naito T, Hashimoto H, Okubo S, Udagawa H, Goto K, Tsuboi M, Ochiai A, Ishii G.

Pathol Int. 2019 Aug;69(8):472-480. doi: 10.1111/pin.12838. Epub 2019 Jul 24.

PMID:
31339210
10.

Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells.

Nakamura H, Sugano M, Miyashita T, Hashimoto H, Ochiai A, Suzuki K, Tsuboi M, Ishii G.

Lung Cancer. 2019 Aug;134:100-107. doi: 10.1016/j.lungcan.2019.04.007. Epub 2019 Apr 8.

PMID:
31319967
11.

A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.

Naito T, Udagawa H, Sato J, Horinouchi H, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Zenke Y, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, Ohe Y, Ishii G, Goto K.

J Thorac Oncol. 2019 Oct;14(10):1818-1827. doi: 10.1016/j.jtho.2019.06.019. Epub 2019 Jun 28.

PMID:
31260834
12.

Dexamethasone Increases Cisplatin-Loaded Nanocarrier Delivery and Efficacy in Metastatic Breast Cancer by Normalizing the Tumor Microenvironment.

Martin JD, Panagi M, Wang C, Khan TT, Martin MR, Voutouri C, Toh K, Papageorgis P, Mpekris F, Polydorou C, Ishii G, Takahashi S, Gotohda N, Suzuki T, Wilhelm ME, Melo VA, Quader S, Norimatsu J, Lanning RM, Kojima M, Stuber MD, Stylianopoulos T, Kataoka K, Cabral H.

ACS Nano. 2019 Jun 25;13(6):6396-6408. doi: 10.1021/acsnano.8b07865. Epub 2019 Jun 12.

PMID:
31187975
13.

Growth patterns of small peripheral squamous cell carcinoma of the lung and their impacts on pathological and biological characteristics of tumor cells.

Omori T, Aokage K, Nakamura H, Katsumata S, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Ikeda N, Tsuboi M, Ishii G.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1773-1783. doi: 10.1007/s00432-019-02937-9. Epub 2019 May 21.

PMID:
31115670
14.

Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3.

Maeda M, Takeshima H, Iida N, Hattori N, Yamashita S, Moro H, Yasukawa Y, Nishiyama K, Hashimoto T, Sekine S, Ishii G, Ochiai A, Fukagawa T, Katai H, Sakai Y, Ushijima T.

Gut. 2019 May 13. pii: gutjnl-2018-317645. doi: 10.1136/gutjnl-2018-317645. [Epub ahead of print]

PMID:
31085554
15.

Prognostic Impact of the Number of Metastatic Lymph Nodes on the Eighth Edition of the TNM Classification of NSCLC.

Katsumata S, Aokage K, Ishii G, Nakasone S, Sakai T, Okada S, Miyoshi T, Tane K, Tsuboi M.

J Thorac Oncol. 2019 Aug;14(8):1408-1418. doi: 10.1016/j.jtho.2019.04.016. Epub 2019 May 2.

PMID:
31055075
16.

Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.

Naito T, Umemura S, Nakamura H, Zenke Y, Udagawa H, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, Aokage K, Tsuboi M, Ishii G, Goto K.

Thorac Cancer. 2019 May;10(5):1285-1288. doi: 10.1111/1759-7714.13070. Epub 2019 Apr 10.

17.

Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.

Miyoshi T, Aokage K, Katsumata S, Tane K, Ishii G, Tsuboi M.

Ann Thorac Surg. 2019 Jul;108(1):249-255. doi: 10.1016/j.athoracsur.2019.01.079. Epub 2019 Mar 12.

PMID:
30876742
18.

The association analysis between HLA-A*26 and Behçet's disease.

Nakamura J, Meguro A, Ishii G, Mihara T, Takeuchi M, Mizuki Y, Yuda K, Yamane T, Kawagoe T, Ota M, Mizuki N.

Sci Rep. 2019 Mar 14;9(1):4426. doi: 10.1038/s41598-019-40824-y.

19.

Stapling cartridge lavage cytology in limited resection for pulmonary malignant tumors: assessment of cytological status of the surgical margin.

Miyoshi T, Yoshida J, Aokage K, Tane K, Ishii G, Tsuboi M.

Heliyon. 2019 Feb 15;5(2):e01240. doi: 10.1016/j.heliyon.2019.e01240. eCollection 2019 Feb.

20.

Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer.

Suzuki J, Kojima M, Aokage K, Sakai T, Nakamura H, Ohara Y, Tane K, Miyoshi T, Sugano M, Fujii S, Kuwata T, Ochiai A, Ito M, Suzuki K, Tsuboi M, Ishii G.

Virchows Arch. 2019 May;474(5):569-575. doi: 10.1007/s00428-019-02535-7. Epub 2019 Feb 14.

PMID:
30762121
21.

Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.

Kadota T, Seo S, Fuse H, Ishii G, Itoh K, Yano T, Kaneko K, Tsukasaki K.

Cancer Med. 2019 Mar;8(3):982-989. doi: 10.1002/cam4.1982. Epub 2019 Feb 7.

22.

Endoscopic submucosal resection using a ligation device without injection for duodenal neuroendocrine tumors.

Oono Y, Shinmura K, Hori K, Yoda Y, Ishii G, Ikematsu H, Yano T.

Surg Endosc. 2019 Jun;33(6):2008-2014. doi: 10.1007/s00464-018-06642-5. Epub 2019 Jan 2.

PMID:
30604268
23.

Radiologic Criteria in Predicting Pathologic Less Invasive Lung Cancer According to TNM 8th Edition.

Katsumata S, Aokage K, Nakasone S, Sakai T, Okada S, Miyoshi T, Tane K, Hayashi R, Ishii G, Tsuboi M.

Clin Lung Cancer. 2019 Mar;20(2):e163-e170. doi: 10.1016/j.cllc.2018.11.001. Epub 2018 Nov 15.

PMID:
30559083
24.

Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma.

Sakai T, Aokage K, Neri S, Nakamura H, Nomura S, Tane K, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Iyoda A, Tsuboi M, Ishii G.

Lung Cancer. 2018 Dec;126:64-71. doi: 10.1016/j.lungcan.2018.10.021. Epub 2018 Oct 28.

PMID:
30527194
25.

Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.

Udagawa H, Umemura S, Murakami I, Mimaki S, Makinoshima H, Ishii G, Miyoshi T, Kirita K, Matsumoto S, Yoh K, Niho S, Tsuchihara K, Goto K.

Lung Cancer. 2018 Dec;126:182-188. doi: 10.1016/j.lungcan.2018.11.014. Epub 2018 Nov 12.

PMID:
30527185
26.

Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia.

Ueda T, Aokage K, Mimaki S, Tane K, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Kusumoto M, Suzuki K, Tsuchihara K, Nishikawa H, Goto K, Tsuboi M, Ishii G.

Lung Cancer. 2018 Dec;126:162-169. doi: 10.1016/j.lungcan.2018.11.006. Epub 2018 Nov 6.

PMID:
30527182
27.

Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators?

Oki T, Hishida T, Yoshida J, Goto M, Sekihara K, Miyoshi T, Aokage K, Ishii G, Tsuboi M.

Eur J Cardiothorac Surg. 2019 May 1;55(5):942-947. doi: 10.1093/ejcts/ezy384.

PMID:
30476033
28.

Spatiotemporal characteristics of fibroblasts-dependent cancer cell invasion.

Miyashita T, Omori T, Nakamura H, Sugano M, Neri S, Fujii S, Hashimoto H, Tsuboi M, Ochiai A, Ishii G.

J Cancer Res Clin Oncol. 2019 Feb;145(2):373-381. doi: 10.1007/s00432-018-2798-y. Epub 2018 Nov 23.

PMID:
30470886
29.

Clinical prediction of solitary pulmonary nodule after a curative resection for gastric cancer.

Kanai R, Tane K, Ishii G, Suzuki J, Sakai T, Okada S, Miyoshi T, Aokage K, Tsuboi M.

Jpn J Clin Oncol. 2018 Dec 1;48(12):1083-1087. doi: 10.1093/jjco/hyy146.

PMID:
30321372
30.

Differences of tumor microenvironment between stage I lepidic-positive and lepidic-negative lung adenocarcinomas.

Katsumata S, Aokage K, Miyoshi T, Tane K, Nakamura H, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Hayashi R, Tsuboi M, Ishii G.

J Thorac Cardiovasc Surg. 2018 Oct;156(4):1679-1688.e2. doi: 10.1016/j.jtcvs.2018.05.053. Epub 2018 Jun 4.

PMID:
30257286
31.

[A Case of Metachronous Cancer Originating from Five Different Organs].

Murakami M, Kimura T, Iwamoto M, Honda M, Ishii G, Koike Y, Sasaki H, Furuta A, Miki K, Ikegami M, Egawa S.

Hinyokika Kiyo. 2018 May;64(5):231-234. doi: 10.14989/ActaUrolJap_64_5_231. Japanese.

32.

Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway.

Yamazaki S, Higuchi Y, Ishibashi M, Hashimoto H, Yasunaga M, Matsumura Y, Tsuchihara K, Tsuboi M, Goto K, Ochiai A, Ishii G.

Cancer Sci. 2018 Jun;109(6):2063-2073. doi: 10.1111/cas.13624.

33.

Utility of Site-Specific Biopsy for Diagnosis of Desmoplastic Malignant Mesothelioma.

Sakai T, Tane K, Usui Y, Miyoshi T, Matsumoto S, Aokage K, Goto K, Suzuki M, Ishii G, Tsuboi M.

Ann Thorac Surg. 2018 Sep;106(3):e125-e128. doi: 10.1016/j.athoracsur.2018.02.062. Epub 2018 Mar 28.

PMID:
29601807
34.

Podoplanin: An emerging cancer biomarker and therapeutic target.

Krishnan H, Rayes J, Miyashita T, Ishii G, Retzbach EP, Sheehan SA, Takemoto A, Chang YW, Yoneda K, Asai J, Jensen L, Chalise L, Natsume A, Goldberg GS.

Cancer Sci. 2018 May;109(5):1292-1299. doi: 10.1111/cas.13580. Review.

35.

The ratio of cancer cells to stroma within the invasive area is a histologic prognostic parameter of lung adenocarcinoma.

Ichikawa T, Aokage K, Sugano M, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Suzuki K, Tsuboi M, Ishii G.

Lung Cancer. 2018 Apr;118:30-35. doi: 10.1016/j.lungcan.2018.01.023. Epub 2018 Jan 31.

PMID:
29571999
36.

Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma.

Nakasone S, Mimaki S, Ichikawa T, Aokage K, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Tsuboi M, Goto K, Tsuchihara K, Ishii G.

J Cancer Res Clin Oncol. 2018 May;144(5):893-900. doi: 10.1007/s00432-018-2619-3. Epub 2018 Mar 6.

PMID:
29511884
37.

Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.

Makinoshima H, Umemura S, Suzuki A, Nakanishi H, Maruyama A, Udagawa H, Mimaki S, Matsumoto S, Niho S, Ishii G, Tsuboi M, Ochiai A, Esumi H, Sasaki T, Goto K, Tsuchihara K.

Cancer Res. 2018 May 1;78(9):2179-2190. doi: 10.1158/0008-5472.CAN-17-2109. Epub 2018 Feb 28.

38.

Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.

Ueda T, Aokage K, Nishikawa H, Neri S, Nakamura H, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Kusumoto M, Suzuki K, Tsuboi M, Ishii G.

J Cancer Res Clin Oncol. 2018 May;144(5):835-844. doi: 10.1007/s00432-018-2602-z. Epub 2018 Feb 12.

PMID:
29435735
39.

A secondary RET mutation in the activation loop conferring resistance to vandetanib.

Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G, Ichikawa H, Nagatoishi S, Tsumoto K, Okuno Y, Yoh K, McDonald NQ, Goto K.

Nat Commun. 2018 Feb 12;9(1):625. doi: 10.1038/s41467-018-02994-7.

40.

Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.

Nakamura H, Ichikawa T, Nakasone S, Miyoshi T, Sugano M, Kojima M, Fujii S, Ochiai A, Kuwata T, Aokage K, Suzuki K, Tsuboi M, Ishii G.

Lung Cancer. 2018 Jan;115:56-63. doi: 10.1016/j.lungcan.2017.11.013. Epub 2017 Nov 20.

PMID:
29290263
41.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.

Aokage K, Miyoshi T, Ishii G, Kusumoto M, Nomura S, Katsumata S, Sekihara K, Tane K, Tsuboi M.

J Thorac Oncol. 2018 Apr;13(4):533-542. doi: 10.1016/j.jtho.2017.11.129. Epub 2017 Dec 13.

42.

Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.

Ichikawa T, Saruwatari K, Mimaki S, Sugano M, Aokage K, Kojima M, Hishida T, Fujii S, Yoshida J, Kuwata T, Ochiai A, Suzuki K, Tsuboi M, Goto K, Tsuchihara K, Ishii G.

Lung Cancer. 2017 Nov;113:134-139. doi: 10.1016/j.lungcan.2017.10.001. Epub 2017 Oct 5.

PMID:
29110840
43.

Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification.

Aokage K, Miyoshi T, Ishii G, Kusumoto M, Nomura S, Katsumata S, Sekihara K, Hishida T, Tsuboi M.

J Thorac Oncol. 2017 Sep;12(9):1403-1412. doi: 10.1016/j.jtho.2017.06.003. Epub 2017 Jun 13.

44.

CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.

Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, Udagawa H, Kirita K, Matsumoto S, Umemura S, Yoh K, Niho S, Tsuboi M, Masutomi K, Goto K, Ochiai A, Ishii G.

Sci Rep. 2017 Apr 21;7:46662. doi: 10.1038/srep46662.

45.

A novel method to generate single-cell-derived cancer-associated fibroblast clones.

Hashimoto H, Suda Y, Miyashita T, Ochiai A, Tsuboi M, Masutomi K, Kiyono T, Ishii G.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1409-1419. doi: 10.1007/s00432-017-2409-3. Epub 2017 Mar 31.

PMID:
28364361
46.

Fibroblast-led cancer cell invasion is activated by epithelial-mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma.

Neri S, Miyashita T, Hashimoto H, Suda Y, Ishibashi M, Kii H, Watanabe H, Kuwata T, Tsuboi M, Goto K, Menju T, Sonobe M, Date H, Ochiai A, Ishii G.

Cancer Lett. 2017 Jun 1;395:20-30. doi: 10.1016/j.canlet.2017.02.026. Epub 2017 Mar 9.

PMID:
28286261
47.

Crosstalk Between Cancer Associated Fibroblasts and Cancer Cells in the Tumor Microenvironment After Radiotherapy.

Ishii G.

EBioMedicine. 2017 Mar;17:7-8. doi: 10.1016/j.ebiom.2017.03.004. Epub 2017 Mar 4. No abstract available.

48.

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.

Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii G, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S.

Cancer Sci. 2017 Apr;108(4):696-703. doi: 10.1111/cas.13190. Epub 2017 Apr 12.

49.

Single cell time-lapse analysis reveals that podoplanin enhances cell survival and colony formation capacity of squamous cell carcinoma cells.

Miyashita T, Higuchi Y, Kojima M, Ochiai A, Ishii G.

Sci Rep. 2017 Jan 6;7:39971. doi: 10.1038/srep39971.

50.

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, Tsuchihara K, Ishii G, Nomura S, Sato A, Ohtsu A, Ohe Y, Goto K.

Lancet Respir Med. 2017 Jan;5(1):42-50. doi: 10.1016/S2213-2600(16)30322-8. Epub 2016 Nov 4.

PMID:
27825616

Supplemental Content

Support Center